Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic

Immune checkpoint inhibitors (ICPIs) have revolutionized the management and prognosis of fit patients with advanced non-small cell lung cancer (NSCLC). Recently, the publication of 5-year survival rates has cemented the role of ICPIs in NSCLC. An ongoing challenge is to determine the optimal treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedlaender, Alex, Kim, Chul, Addeo, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239024/
https://www.ncbi.nlm.nih.gov/pubmed/32574277
http://dx.doi.org/10.3389/fonc.2020.00862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239024/
https://www.ncbi.nlm.nih.gov/pubmed/32574277
http://dx.doi.org/10.3389/fonc.2020.00862

Ejemplares similares